Subscribe To
TXG / Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation
![Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation](https://cdn.snapi.dev/images/v1/2/8/biotech27-1972810.jpg)
TXG News
![10x Genomics: Unveiling The Investment Potential 10x Genomics: Unveiling The Investment Potential](https://cdn.snapi.dev/images/v1/e/0/image-1393990757-2140331.jpg)
By Seeking Alpha
November 4, 2023
10x Genomics: Unveiling The Investment Potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenu more_horizontal
![10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript 10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/9/n/transcript35-2138363.jpg)
By Seeking Alpha
November 2, 2023
10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor more_horizontal
![10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates](https://cdn.snapi.dev/images/v1/s/u/default11-2138250.jpg)
By Zacks Investment Research
November 2, 2023
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth more_horizontal
![10x Genomics: Recent Performance Amplifies My Bullish Conviction 10x Genomics: Recent Performance Amplifies My Bullish Conviction](https://cdn.snapi.dev/images/v1/h/h/image-135899648-2055631.jpg)
By Seeking Alpha
September 8, 2023
10x Genomics: Recent Performance Amplifies My Bullish Conviction
10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance i more_horizontal
![10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say 10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say](https://cdn.snapi.dev/images/v1/9/q/default27-2006650.jpg)
By Zacks Investment Research
August 3, 2023
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be w more_horizontal
![10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/i/l/default45-2006443.jpg)
By Zacks Investment Research
August 3, 2023
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of more_horizontal
![Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation](https://cdn.snapi.dev/images/v1/2/8/biotech27-1972810.jpg)
By 24/7 Wall Street
July 14, 2023
Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation
Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation. more_horizontal
![10x Genomics: Growth Outweighing The Risks 10x Genomics: Growth Outweighing The Risks](https://cdn.snapi.dev/images/v1/m/h/image-1407235569-1946827.jpg)
By Seeking Alpha
June 24, 2023
10x Genomics: Growth Outweighing The Risks
10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics more_horizontal